2Año·

Quarterly figures from 19.10.2022...

Briefly summarized ⤵️



Everything that comes tonight or after hours, is then possibly only in the morning. I'm sure I don't have all of them here, but only the larger ones. Tell me gladly times which you still so missing?


$ABT (+1,31 %)
Abbott Laboratories:

Surpassed analyst estimates of $0.95 in the third quarter with earnings per share of $1.15. Revenue of $10.4 billion exceeded expectations of $9.63 billion.


$PG (+1,99 %)
The Procter & Gamble Co:

First-quarter earnings per share of $1.57 beat analyst estimates of $1.56. Sales of $20.6 billion beat expectations of $20.37 billion. In its outlook for 2023, the company continues to see organic sales growth of 3% to 5%. Earnings per share are now expected at the lower end of guidance due to currency impacts.


$NESN (-1,05 %)
Nestlé:

Posts Q1-3 sales of CHF 69.13 billion (analyst forecast: CHF 69.05 billion), organic growth of 8.5% (analyst forecast: +8.3%) and RIG of +1.0% (forecast: +1.1%). In the outlook for 2022, Nestlé confirms its margin outlook and expects sales growth of 8% (previously: 7-8%).


$SRT (+1,96 %)
Sartorius:

Reports Q3 sales revenue of €1.05 billion (previous year: €898 million, analyst forecast: €1.06 billion), order intake of €952.4 million (previous year: €1.1 billion, forecast: €1.08 billion), Ebitda (adjusted) of €354 million (previous year: €311 million, forecast: €357 million) and net profit (adjusted) of €167.3 million (previous year: €148 million). In its outlook for fiscal 2022, the company expects revenue growth in the lower half of the 15% to 19% range; the adjusted Ebitda margin target is confirmed at 34%.


$ASML (+2,04 %)
ASML:

Posts Q3 revenue of €5.78 billion (previous quarter: €5.4 billion, analyst forecast: €5.3 billion), gross margin of 51.8% (previous year: 49.1%, analyst forecast: 49.4%) and net income of €1.7 billion (previous quarter: 1.4 billion, forecast: €1.37 billion). In its Q4 outlook, the company expects sales of €6.1 to €6.6 billion (forecast: €6.04 billion), gross margin of around 49% (analyst forecast: 49.95%) and fiscal year sales of €21.1 billion.


This will be followed this evening by:

$TSLA (+1,27 %)
$IBM (-0,97 %)
$63DB (+0,01 %)
$AA (+0,58 %)


#tesla
#ibm
#deutschebörse
#alcoa
#satorius
#quartalszahlen
#prognose
#aktientipps
#aktien
#community
#communityfeedback
#aktienmarkt
#earnings
#lernen

attachment
24
14 Comentarios

Imagen de perfil
Thank you !
3
Imagen de perfil
@Barsten i just love the quarter season :)... where i still traded, much more but i still like to watch the important ones.
1
Imagen de perfil
The hashtags didn't quite work 😅 But thanks for summarizing :)
1
Imagen de perfil
@RoronoaZoro I have also noticed. Today in the posts for the first time with hashtags tried. But somehow I was too stupid. Had done that on the iPad with the app. Must look at me times in the browser.
Imagen de perfil
@MitVerstandzumKapital you have to click like when marking I think when the suggestion comes I learned 😅
1
Imagen de perfil
@RoronoaZoro ok that did not work in the app, there was no suggestion. I look at the same time on the phone and try to edit.
1
Imagen de perfil
Abbott has been given a huge bashing 🥴
1
Imagen de perfil
@Der_Dividenden_Monteur yes, you have to take a close look, either more was expected in the outlook or it is a sell on good news... haven't looked at it myself yet.
1
Imagen de perfil
@MitVerstandzumKapital I think I read something that there are still lawsuits because of the contaminated baby food.
1
Imagen de perfil
@Der_Dividenden_Monteur oh great, thanks for. I will continue to pursue this approach.
1
Imagen de perfil
@MitVerstandzumKapital according to seeking alpha, a large part of the profit was also due to covid tests, which was probably also punished
1
Imagen de perfil
@Der_Dividenden_Monteur The entire healthcare and pharmaceutical sector is taking a beating today. Abbott and Sartorius are probably dragging the competition down with them?
1
Imagen de perfil
@RegularJohn well not quite, J&J at just -0.19 and Merck&Co +0.21 I'm more surprised that Abbvie is holding so stable, it's a spin-off of Abbott
Imagen de perfil
@Der_Dividenden_Monteur would also not call on the get. Yesterday was also extreme again and today it just grinds a bit. But certainly pulls Abbott and Co, the rest also something with.
1
Únase a la conversación